New hemophilia drug hympavzi put to the test in real-world safety check
NCT ID NCT07161687
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 31 times
Summary
This study looks at the safety of the drug Hympavzi in 50 people with congenital hemophilia A or B who do not have inhibitors. Researchers will track any side effects related to the drug. The goal is to see how well the drug works in everyday use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A OR B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.